Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

In FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty-two per cent of patients treated with intention-to-transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain in long-term remission (median follow-up 43 months).